bioAffinity Technologies, Inc.
BIAF • NASDAQ
bioAffinity Technologies, Inc. is a medical - diagnostics & research company in the healthcare sector trading on NASDAQ, led by CEO Maria Zannes, with a market cap of $3.4M.
CEOMaria Zannes
Market Cap$3.4M
Medical - Diagnostics & Research
Healthcare
Employees75.0
Websitebioaffinitytech.com
Country
United States of America
Next Earnings
Upcoming earnings announcement for bioAffinity Technologies, Inc.
Date
Monday, March 30, 2026 (in 2 months)
Timing
Before Market Open (9:00 AM New York)
Fiscal Period
Q4 2025
EPS Estimate
-$2.70
Revenue Estimate
$1.4M
Earnings History
Past 12 earnings reports for bioAffinity Technologies, Inc.
| Date | Period | EPS | EPS Surprise | Revenue | Rev. Surprise | Filing |
|---|---|---|---|---|---|---|
| Nov 14, 2025 | Q3 2025 | -$4.74Est: -$2.70 | -75.6% | $1.4MEst: $1.4M | +2.5% |  10-Q |
| Aug 14, 2025 | Q2 2025 | -$0.17Est: -$0.10 | -70.0% | $1.3MEst: $1.5M | -15.7% | 10-Q |
| May 15, 2025 | Q1 2025 | -$0.16Est: -$0.16 | 0.0% | $1.9MEst: $2.1M | -12.1% | 10-Q |
| Mar 31, 2025 | Q4 2024 | -$0.21Est: -$0.14 | -50.0% | $2.2MEst: $2.4M | -8.8% | 10-K/A |
| Nov 14, 2024 | Q3 2024 | -$0.16Est: -$0.15 | -6.7% | $2.4MEst: $2.5M | -7.5% | 10-Q |
| Aug 14, 2024 | Q2 2024 | -$0.19 | — | $2.4M | — | 10-Q |
| May 15, 2024 | Q1 2024 | -$0.21 | — | $2.4M | — | 10-Q |
| Apr 1, 2024 | Q4 2023 | -$0.26 | — | $2.2M | — | — |
| Nov 14, 2023 | Q3 2023 | -$0.26 | — | $298.5K | — | — |
| Aug 14, 2023 | Q2 2023 | -$0.20 | — | $19.7K | — | 10-Q |
| May 15, 2023 | Q1 2023 | -$0.18 | — | $921.0K | — | 10-Q |
| Mar 31, 2023 | Q4 2022 | -$0.44 | — | $2.3M | — | — |